Government Advised Against Reclassifying Ketamine
Experts advising the UK government on drug policy have recommended that ketamine should remain classified as a Class B drug, rather than being upgraded to Class A. This decision follows a record increase in illegal use of the substance, which has prompted calls for its reclassification.
Current Status of Ketamine
At present, ketamine is classified as a Class B drug. It is utilised in clinical settings, primarily as an anaesthetic for both humans and animals. However, it is also often used recreationally in its powdered form. In January 2023, the government initiated a review of ketamine’s classification in light of rising concerns about its illegal use, which reached unprecedented levels by March of the same year.
Findings of the Advisory Council on the Misuse of Drugs
The Advisory Council on the Misuse of Drugs (ACMD) delivered its recommendations on this matter recently, stating that the suggestion to keep ketamine as a Class B drug was not reached unanimously. The ACMD is a non-departmental public body sponsored by the Home Office, composed of experts from various fields, including academia, law enforcement, and healthcare.
In their report, the ACMD concluded that the potential benefits of reclassifying ketamine did not outweigh the drawbacks. Major concerns included the possibility of increased stigma attached to ketamine use, which could discourage individuals from seeking help for addiction.
Concerns Surrounding Reclassification
The report outlined several adverse effects that might arise from elevating ketamine’s status to Class A. These included:
- Heightened stigma making it harder for users to access support services.
- Increased enforcement measures that could lead to more expensive drug prices and a higher risk of supply adulteration.
- Potentially more crime associated with the illegal drug trade.
Furthermore, individuals with personal experience of ketamine use voiced skepticism about whether reclassification would actually reduce use. Some healthcare professionals, however, supported the idea of reclassification to address the drug’s significant impact on users.
Public Health Approach Recommended
Despite not endorsing reclassification, the ACMD urged the adoption of a comprehensive public health strategy to manage ketamine use. This included calls for improved services for those affected by ketamine addiction, particularly among young people. Their report highlighted the inadequacy of current support systems.
The ACMD suggested several actions for the government, such as:
- Identifying countries where significant amounts of illegal ketamine originate.
- Engaging in discussions with foreign governments to curb supply.
- Expanding testing for ketamine in roadside checks and during arrests.
- Ensuring that health services routinely collect data on ketamine-related incidents.
Reactions from Stakeholders
Responses to the ACMD’s recommendations were mixed. Various frontline workers supporting ketamine users expressed no surprise at the decision and emphasised the importance of robust support systems over strict legal penalties. Conversely, some parents who have lost children to ketamine-related issues expressed disappointment at the council’s decision.
In response to these developments, a spokesperson from the Home Office acknowledged the dangers of ketamine and expressed deep concern regarding its rising misuse. They confirmed that the government would review the ACMD’s findings and respond promptly.
Background
The conversation surrounding ketamine’s classification is part of a broader discourse on drug policy in the UK. The examination of its impact on public health and safety, particularly amidst increasing addiction rates, has sparked significant interest and debate among policymakers and the general public alike.
Source: Original Article
